e.g. mhealth
Search Results (1 to 3 of 3 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 2 JMIR Cardio
- 1 JMIR mHealth and uHealth
- 0 Journal of Medical Internet Research
- 0 Medicine 2.0
- 0 Interactive Journal of Medical Research
- 0 iProceedings
- 0 JMIR Research Protocols
- 0 JMIR Human Factors
- 0 JMIR Medical Informatics
- 0 JMIR Public Health and Surveillance
- 0 JMIR Serious Games
- 0 JMIR Mental Health
- 0 JMIR Rehabilitation and Assistive Technologies
- 0 JMIR Preprints
- 0 JMIR Bioinformatics and Biotechnology
- 0 JMIR Medical Education
- 0 JMIR Cancer
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 JMIR Formative Research
- 0 Journal of Participatory Medicine
- 0 JMIR Dermatology
- 0 JMIR Pediatrics and Parenting
- 0 JMIR Aging
- 0 JMIR Perioperative Medicine
- 0 JMIR Nursing
- 0 JMIRx Med
- 0 JMIRx Bio
- 0 JMIR Infodemiology
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 Online Journal of Public Health Informatics
- 0 JMIR XR and Spatial Computing (JMXR)
Atherosclerotic cardiovascular disease (ASCVD) remains one of the leading causes of death worldwide [1] and is a burden to medical expenses in Europe [2]. The occurrence of ASCVD is highly correlated with conventional risk factors such as high blood pressure and smoking. Therefore, prevention and treatment of risk factors is of importance in reducing this burden. ASCVD can be prevented to a great extent by a healthy lifestyle [3].
JMIR Cardio 2022;6(2):e37437
Download Citation: END BibTex RIS
Following recommendations of Goff et al [12], which outlines the process of developing a risk equation for predicting the 10-year ASCVD risk of individuals between the ages of 40 and 79 years, from our dataset, we identified patients aged 40 to 79 years and without a prior history of ASCVD documented in their EMR. Of these patients, we identified 181 with a calculated 10-year primary risk of ASCVD score in their EMR.
JMIR Cardio 2021;5(1):e24473
Download Citation: END BibTex RIS
This study is the development phase of a proposed m Health intervention, the txt2heart trial, to support patient adherence to medications for atherosclerotic cardiovascular disease (ASCVD). This is an area of much-needed support as, globally, many individuals with risk factors for ASCVD remain undiagnosed, untreated, and uncontrolled [14-16].
JMIR Mhealth Uhealth 2019;7(5):e10465
Download Citation: END BibTex RIS